'Weeding the garden' lets anaplastic lymphoma kinase-positive lung cancer patients continue crizotinib
Wednesday, January 29, 2014 - 08:00
in Health & Medicine
Patients taking crizotinib for anaplastic lymphoma kinase-positive non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease, according to a new study.